Özet:

Introduction: At the beginning of the reduction of complications, 5-10% weight loss has shown significant clinical benefits in obesity. In this study, the new diagnosis of a three-month lifestyle change and effective weight loss at the end of pharmacological treatment was studied by basic clinical parameters and was unpredictable. Methods: In this retrospective study, 58 new diagnoses of non-known comorbid disease compared the three-month lifestyle changes of the morbid obesity patient and after pharmacological treatment with anthropometric measurements, blood pressure, lipite profile, hunger glucose and insulin levels, hepatic enzymes, and HBA1c levels with pre- and after-treatment results. Initially, weight loss rates were calculated and grouped as less than 5% (group 1, n = 13), 5%-10 (group 2, n = 24), 10% above (group 3, n = 21) weight loss. Results: The initial body-mass index dropped to 39.96 kg/m2 at the end of three months while the average was 42.78 kg/m2. Median weight loss was found 9 kg (quarterly interval, 6-13 kg). The average basal HBA1c level was the highest in group 3. According to Pearson's correlation analysis, a significant correlation in the positive direction was observed between the basal average HBA1c level and weight loss (rho: 0.468, p < 0.001). When the multivariant logistics regression analysis was created with basic clinical and laboratory parameters to predict weight loss of more than 10%, only the basic HBA1c level was found meaningful (Odds ratio = 5.2 [95% Confidence range 1.03-26. 15], p < 0.05. The result: The new diagnosis is that when pharmacological treatment is given with a three-month lifestyle change in morbid obesity, the beginning of HBA1c levels may be more effective in weight loss.

Anahtar Kelimeler: